Clinical Trial Update: Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update investigating the first-line use of amivantamab, lazertinib, and pemetrexed in recurrent/metastatic EGFR-mutant non-small cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Lazertinib (lazertinib)
• RYBREVANT (amivantamab-vmjw)

Snippet

Sponsor: Latin American Cooperative Oncology Group | Conditions: Metastatic Non-small Cell Lung Cancers | Phase 2 | Status: ACTIVE_NOT_RECRUITING